Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significance of erb-B2 immunoreactivity in cervical cancer.
Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, DiVagno G, Silvestro G, Tambaro R, Formato R, Iaffaioli VR, Di Maio M, Pignata S. Califano D, et al. Front Biosci. 2006 Sep 1;11:2071-6. doi: 10.2741/1949. Front Biosci. 2006. PMID: 16720293
FEZ1/LZTS1 protein expression in ovarian cancer.
Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, Cirombella R, Fusco A, Chiappetta G. Califano D, et al. J Cell Physiol. 2010 Feb;222(2):382-6. doi: 10.1002/jcp.21962. J Cell Physiol. 2010. PMID: 19885841
BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.
Chiappetta G, Basile A, Arra C, Califano D, Pasquinelli R, Barbieri A, De Simone V, Rea D, Giudice A, Pezzullo L, De Laurenzi V, Botti G, Losito S, Conforti D, Turco MC. Chiappetta G, et al. Among authors: califano d. J Clin Endocrinol Metab. 2012 Jan;97(1):E115-20. doi: 10.1210/jc.2011-0484. Epub 2011 Nov 9. J Clin Endocrinol Metab. 2012. PMID: 22072743
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, Califano D, Pignata S, Losito S, Canzonieri V, Sorio R, Alder H, Wernicke D, Stoppacciaro A, Baldassarre G, Croce CM. Vecchione A, et al. Among authors: califano d. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9845-50. doi: 10.1073/pnas.1305472110. Epub 2013 May 22. Proc Natl Acad Sci U S A. 2013. PMID: 23697367 Free PMC article.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Bagnoli M, et al. Among authors: califano d. Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9. Lancet Oncol. 2016. PMID: 27402147 Free article.
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.
Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S. Perrone F, et al. Among authors: califano d. Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056. Oncotarget. 2016. PMID: 27655643 Free PMC article. Clinical Trial.
92 results